Dr Andrew Round is an experienced Investor and biotech entrepreneur with more than 20 years’ experience sourcing, structuring, and managing high growth investments across healthcare, life sciences, deep tech, and university spinouts. Over his career, he has been involved in 100+ early stage company investments, participated in 20+ successful exits, and helped raise and deploy over £200 million into innovative businesses.
Currently Senior Investment Director at Deepbridge Capital, Andrew works alongside the CIO to manage a 74 company healthcare portfolio, drive later stage exit strategies, and shape investment strategy for the EIS funds. He recently led the deployment of the SEIS UK Innovation Fund, completing investments into 12 university spinouts in just twelve weeks, while also introducing new investors, advisors, and NEDs to strengthen portfolio growth.
Previously, Andrew was Director and Head of Life Sciences at Praetura Ventures, where he helped grow the firm to over £125 million AUM in less than 3 years, secured and scaled the £20 million GMCII mandate, and completed high value deals across wound care, diagnostics, and pharmaceutical switching. His investments include Inotec, which has since achieved a 4× value uplift and raised £25 million in strategic follow on funding, and Reacta Healthcare, which secured a £15 million pharmaceutical partnership following investment (5x value uplift).
His earlier roles include senior investment positions at Maven Capital Partners, Alliance Fund Managers (NPIF), and SPARK Impact, where he invested £20 million into 25 biomedical companies and increased SPARK’s fund from £25 million to £35 million, achieving top quartile performance with projected 3.5× returns. He led multiple exits, including Cerus Endovascular exited to Stryker for £525m.
Before moving into venture, Andrew held commercial and strategic positions at the Centre for Process Innovation, IP Group (£1bn AUM investor in university spinouts), and Yet2.com, delivering technology licensing agreements, spinout creation, and multi million pound acquisitions for global corporates such as Siemens, P&G, Kimberly Clark, Philips, and Sumitomo Chemical. He began his career as founder at Micap plc, a technology company based on his PhD raising £70m to develop the company’s platform, negotiate global licence deals and acquire additional companies.
Andrew holds a PhD in Biochemistry (Yeast Microencapsulation Technology) from the University of Leeds. He is recognised for his deep sector knowledge, disciplined investment process, strong network across UK universities and healthcare ecosystems, and a consistent track record of unlocking value in early stage science and technology companies.